Granules India is currently trading at Rs. 101.30, down by 10.95 points or 9.76% from its previous closing of Rs. 112.25 on the BSE.
The scrip opened at Rs. 107.10 and has touched a high and low of Rs. 107.10 and Rs. 97.80 respectively. So far 4,26,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 151.15 on 14-Jul-2016 and a 52 week low of Rs. 91.45 on 09-Nov-2016.
Last one week high and low of the scrip stood at Rs. 113.30 and Rs. 97.80 respectively. The current market cap of the company is Rs. 2,195.83 crore.
The promoters holding in the company stood at 51.88%, while Institutions and Non-Institutions held 7.24% and 40.88% respectively.
Granules India has received the inspection report from INFARMED (InstitutoNacional da Farmacia E Do Medicamento), Portugal with 11 observations. The Gagillapur facility manufactures Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). INFARMED Portugal had conducted a renewal inspection on the company’s facility located at Gagillapur, Telangana, India.
The company has initiated necessary steps to address the observations of the inspection agency and will submit its response with a corrective and preventive action plan within stipulated time. The company will also be requesting the INFARMED for re-inspection of the Gagillapur facility at the earliest.
Granules India is a pharmaceutical company with presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1807.25 |
| Dr. Reddys Lab | 1273.90 |
| Cipla | 1388.80 |
| Zydus Lifesciences | 1104.35 |
| Lupin | 2292.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: